Teriparatide in East Asian Postmenopausal Women with Osteoporosis in a Real-World Setting: A Baseline Analysis of the Asia and Latin America Fracture Observational Study (ALAFOS)

Purpose The aim of this analysis is to describe the baseline characteristics of patients who are prescribed teriparatide for the treatment of postmenopausal osteoporosis in a real-world setting in East Asia. Patients and Methods The Asia and Latin America Fracture Observational Study (ALAFOS) is a prospective, multinational, observational study designed to evaluate real-world use of teriparatide in the treatment of postmenopausal osteoporosis in 20 countries across Asia, Latin America, the Middle East, and Russia. This subregional analysis focuses on the East Asian subpopulation of the ALAFOS study. Here we report baseline clinical characteristics, details regarding the history of fractures, risk factors for osteoporosis, comorbidities, osteoporosis treatment, and health-related quality of life in patients enrolled in China, Hong Kong, South Korea, and Taiwan. Results The East Asian subgroup of ALAFOS included 1136 postmenopausal women, constituting 37.5% (1136/3031) of the overall ALAFOS patient population. The mean (SD) age was 75.0 (9.6) years. The mean (SD) bone mineral density T-scores were −3.11 (1.54), −2.58 (1.11), and −2.86 (1.09) at the lumbar spine, total hip, and femoral neck, respectively; 69.6% of patients had experienced at least one fragility fracture and 40.4% had experienced ≥2 fragility fractures after 40 years of age. Overall, 63.3% of patients had used medications for osteoporosis in the past. The mean (SD) EQ-5D-5L Visual Analog Scale (VAS) score at baseline was 59.7 (20.8); the mean (SD) back pain numeric rating scale score for worst pain in the last 24 hrs was 5.2 (3.2). Conclusion Our results indicate that patients who are prescribed teriparatide in East Asia were elderly women with severe osteoporosis, low bone mineral density, high prevalence of fractures, back pain and poor health-related quality of life. Most of the patients received teriparatide as a second-line treatment.

[1]  W. Xia,et al.  The epidemiology of osteoporosis, associated fragility fractures, and management gap in China , 2019, Archives of Osteoporosis.

[2]  R. Burge,et al.  Study description and baseline characteristics of the population enrolled in a multinational, observational study of teriparatide in postmenopausal women with osteoporosis: the Asia and Latin America Fracture Observational Study (ALAFOS) , 2019, Current medical research and opinion.

[3]  R. Takayanagi,et al.  Real-world effectiveness of daily teriparatide in Japanese patients with osteoporosis at high risk for fracture: final results from the 24-month Japan Fracture Observational Study (JFOS) , 2017, Current medical research and opinion.

[4]  C. Cheung,et al.  Osteoporosis in East Asia: Current issues in assessment and management , 2016, Osteoporosis and sarcopenia.

[5]  K. L. Leung,et al.  The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. , 2013, Hong Kong medical journal = Xianggang yi xue za zhi.

[6]  S. Silverman,et al.  The Direct Assessment of Nonvertebral Fractures in Community Experience (DANCE) study: 2-year nonvertebral fragility fracture results , 2013, Osteoporosis International.

[7]  Naoto Endo,et al.  Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.

[8]  C. Cooper,et al.  Geographic Variation in Osteoporotic Hip Fracture Incidence: The Growing Importance of Asian Influences in Coming Decades , 2010, Journal of osteoporosis.

[9]  H. Nam,et al.  Prevalence of osteoporosis and reference data for lumbar spine and hip bone mineral density in a Korean population , 2008, Journal of Bone and Mineral Metabolism.

[10]  W. Lems,et al.  Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting , 2008, Current medical research and opinion.

[11]  H. Barden,et al.  Age-related bone mineral density, bone loss rate, prevalence of osteoporosis, and reference database of women at multiple centers in China. , 2007, Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry.

[12]  O. Johnell,et al.  An estimate of the worldwide prevalence and disability associated with osteoporotic fractures , 2006, Osteoporosis International.

[13]  P. Sambrook,et al.  Guidelines for diagnosing, prevention and treatment of osteoporosis in Asia , 2006 .

[14]  H. Katagiri,et al.  Increasing incidence of hip fracture in Tottori Prefecture, Japan: Trend from 1986 to 2001 , 2005, Osteoporosis International.

[15]  P. Leung,et al.  Bone mineral density reference norms for Hong Kong Chinese , 2005, Osteoporosis International.

[16]  L. Yeh,et al.  Normal bone mineral density in anteroposterior, lateral spine and hip of Chinese men in Taiwan: effect of age change, body weight and height. , 2004, Journal of the Chinese Medical Association : JCMA.

[17]  C. Cooper,et al.  Hip fractures in the elderly: A world-wide projection , 1992, Osteoporosis International.

[18]  K. Tsai,et al.  Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary , 2013, Journal of Bone and Mineral Metabolism.

[19]  P. Sambrook,et al.  The Incidence of Hip Fracture in Four Asian Countries: The Asian Osteoporosis Study (AOS) , 2001, Osteoporosis International.

[20]  M. Iki,et al.  Bone Mineral Density of the Spine, Hip and Distal Forearm in Representative Samples of the Japanese Female Population: Japanese Population-Based Osteoporosis (JPOS) Study , 2001, Osteoporosis International.